About Enzyre
Enzyre is a company based in Nijmegen (Netherlands) founded in 2016. Enzyre has raised $11.88 million across 2 funding rounds from investors including Demcon, Oost NL and i&i Bio. Enzyre offers products and services including ENZYSYSTEM, ENZYCARD, and ENZYPAD. Enzyre operates in a competitive market with competitors including Accriva Diagnostics, Diagnostica Stago, Entegrion, MedicQuant ApS and Perosphere, among others.
- Headquarter Nijmegen, Netherlands
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Enzyre Bv
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11.88 M (USD)
in 2 rounds
-
Latest Funding Round
$11.88 M (USD), Series A
Nov 02, 2022
-
Investors
Demcon
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enzyre
Enzyre offers a comprehensive portfolio of products and services, including ENZYSYSTEM, ENZYCARD, and ENZYPAD.
Integrated platform for blood coagulation analysis and data sharing.
Single-use device for blood sample testing and reagent processing.
Reusable unit that handles blood analysis and transfers results to cloud.
People of Enzyre
Unlock access to complete
Unlock access to complete
Funding Insights of Enzyre
Enzyre has successfully raised a total of $11.88M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11.88 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enzyre
Enzyre has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Demcon, Oost NL and i&i Bio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic VC firm investing in geographies such as the Netherlands
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Early-stage venture capital investment is provided in life sciences.
|
Locked | Locked | Locked |
Investor details for Enzyre
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enzyre
Investment portfolio details for Enzyre
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enzyre
Detailed financials for Enzyre
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enzyre Comparisons
Peer comparison for Enzyre
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enzyre
Enzyre operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accriva Diagnostics, Diagnostica Stago, Entegrion, MedicQuant ApS and Perosphere, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Near-patient diagnostic systems for coagulation testing are developed.
|
|
| Locked | Locked | Locked |
A portfolio of hemostasis and coagulation diagnostic products is manufactured.
|
|
| Locked | Locked | Locked |
Hemostasis and fluid replacement products are provided for medical applications.
|
|
| Locked | Locked | Locked |
Diagnostic kits for blood anticoagulant detection are provided.
|
|
| Locked | Locked | Locked |
Anticoagulant reversal agent and small molecules to prevent allergic reactions, traumatic brain injury.
|
Detailed competitors of Enzyre
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enzyre
Complete news archive for Enzyre
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enzyre
Enzyre was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Enzyre is headquartered in Nijmegen, Netherlands. It is registered at Nijmegen, Gelderland, Netherlands.
Enzyre is a funded company, having raised a total of $11.88M across 2 funding rounds to date.
Enzyre was founded in 2016 and is based in Nijmegen, Netherlands. Operations center on the medical diagnostics sector, where ENZYPAD devices are produced for blood coagulation testing. Painless blood sampling is facilitated through single-use microfluidic cartridges that incorporate necessary reagents and controls. Proprietary latent luciferin-protected peptide substrates are utilized to measure specific enzyme activities in the coagulation cascade.
Enzyre's top competitors include Accriva Diagnostics, Diagnostica Stago and MedicQuant ApS.
Enzyre offers ENZYSYSTEM, ENZYCARD, and ENZYPAD.
Enzyre has 5 investors. Key investors include Demcon, Oost NL, i&i Bio, Novalis Biotech, and Takeda Ventures.